Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

InterCure Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

2024 RESULTS WERE AFFECTED BY DAMAGES TO OUR SOUTHERN FACILITY CAUSED BY THE TERRORIST ATTACK ON OCTOBER 7, 2023, AND THE CONTINUED WAR IN GAZA. INTERCURE IS ENTITLED TO FULL COMPENSATION FROM THE ISRAELI AUTHORITIES FOR ALL DIRECT AND INDIRECT DAMAGES CAUSED TO THE SOUTHERN FACILITY.

INTERCURE ANNOUNCES FY2024 RESULTS AND PROVIDES Q1 2025 UPDATE: REVENUE OF NIS 239 MILLION AND ADJUSTED EBITDA OF NIS 24 MILLION, STRONG START TO 2025

NEW YORK ANDHERZLIYA, ISRAEL , FEB. 12, 2025 /PRNEWSWIRE/ -- INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (DBA CANNDOC) ("INTERCURE" OR THE "COMPANY"), ANNOUNCES TODAY THAT MR.

INTERCURE NAMES ALEXANDER RABINOVICH AS CHAIRMAN REPLACING EHUD BARAK

THE FUNDING MAY INCREASE TO NIS 107M TO SUPPORT THE EXPANSION OF THE FACILITY IN COLLABORATION WITH THE "TKUMAH" ADMINISTRATION, POST-WAR. THE FUNDING INCLUDES INVESTMENTS FROM KEY SHAREHOLDERS OF THE COMPANY, INCLUDING CEO ALEXANDER RABINOVICH, AS WELL AS LEAD INVESTORS YARON YAKOBI AND TZAHI HAGAG WHO WILL BECOME SIGNIFICANT SHAREHOLDERS.

INTERCURE HAS SECURED FUNDING OF NIS 66M TO SUPPORT THE RECOVERY OF NIR OZ FACILITY

NEW YORK AND HERZLIYA, ISRAEL, AUG. 29, 2024 (GLOBE NEWSWIRE) -- INTERCURE LTD .(NASDAQ: INCR) (TASE: INCR) ("INTERCURE" OR THE "COMPANY") IS PLEASED TO ANNOUNCE ITS FINANCIAL AND OPERATING RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024. ALL AMOUNTS ARE EXPRESSED IN NEW ISRAELI SHEKELS (NIS), UNLESS OTHERWISE NOTED.

INTERCURE ANNOUNCES FIRST HALF OF 2024 RESULTS: REVENUE OF NIS 126 MILLION AND ADJUSTED EBITDA OF NIS 21 MILLION

NEW YORK & HERZLIYA, ISRAEL--(BUSINESS WIRE)--INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (DBA CANNDOC) ("INTERCURE" OR THE "COMPANY"), THE LEADING VERTICALLY INTEGRATED MEDICAL CANNABIS COMPANY OUTSIDE OF NORTH AMERICA, IS ANNOUNCING A NEW STRATEGIC AGREEMENT WITH COOKIES, THE GLOBALLY RECOGNIZED CANNABIS BRAND, TO CULTIVATE, MANUFACTURE, IMPORT AND DISTRIBUTE COOKIES' BRANDED PRODUCTS, PRODUCED FROM ITS CULTIVATION AND MANUFACTURING FACILITIES, INITIALLY IN 8 LICENSED BRANDED PHARMACIES ACROSS.

INTERCURE ANNOUNCES EXPANSION OF ITS STRATEGIC PARTNERSHIP WITH COOKIES TO GERMANY

NEW YORK & HERZLIYA, ISRAEL--(BUSINESS WIRE)--INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (DBA CANNDOC), THE LEADING MEDICAL CANNABIS COMPANY OUTSIDE OF NORTH AMERICA, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE CANACCORD GENUITY 8TH ANNUAL GLOBAL CANNABIS CONFERENCE. THE CONFERENCE IS SCHEDULED FOR TOMORROW, MAY 23, 2024, AT THE WESTIN NY GRAND CENTRAL HOTEL IN NEW YORK CITY. THIS PRESTIGIOUS EVENT WILL BRING TOGETHER SENIOR MANAGEMENT TEAMS FROM LEADING CANNABIS COMPANIES INCLUDING INTERCU.

INTERCURE TO PARTICIPATE IN CANACCORD GENUITY'S 8TH ANNUAL GLOBAL CANNABIS CONFERENCE

NEW YORK & HERZLIYA, ISRAEL--(BUSINESS WIRE)--INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) ("INTERCURE" OR THE "COMPANY") TODAY ANNOUNCED RESULTS FOR THE FULL YEAR ENDING DECEMBER 31, 2023. ALL AMOUNTS ARE EXPRESSED IN NEW ISRAELI SHEKELS (NIS), UNLESS OTHERWISE NOTED. FY2023 FINANCIAL HIGHLIGHTS AND MILESTONES ANNUAL REVENUE FOR THE YEAR ENDING DECEMBER 31, 2023 WAS NIS 356 MILLION, AND THE ADJUSTED EBITDA FOR THE YEAR ENDING DECEMBER 31, 2023 WAS NIS 61 MILLION, APPROXIMATELY 17% OF REVENUES, A.

INTERCURE ANNOUNCES FY2023 RESULTS: REVENUE OF NIS 356 MILLION AND ADJUSTED EBITDA OF NIS 61 MILLION

NEW YORK & HERZLIYA, ISRAEL--(BUSINESS WIRE)---- $INCR #CANNABIS--INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (DBA CANNDOC) ("INTERCURE" OR THE "COMPANY"), THE LEADING MEDICAL CANNABIS COMPANY OUTSIDE OF NORTH AMERICA, IS THRILLED TO CONGRATULATE THE FEDERAL REPUBLIC OF GERMANY FOR THE PASSING OF THE CANNG CANNABIS ACT, WHICH IS EXPECTED TO TAKE EFFECT ON APRIL 1, 2024. ON THE BACKDROP OF THIS MONUMENTAL DEVELOPMENT, INTERCURE EXPECTS TO LAUNCH A SERIES OF PRODUCTS IN GERMANY IN THE COMING MONTHS. WHILE THE CANNA.

INTERCURE CONGRATULATES GERMANY ON CANNABIS REFORM, EXPANDING ITS GLOBAL FOOTPRINT

LONDON--(BUSINESS WIRE)---- $INCR #CANNG--THE PESG RESEARCH HAS RELEASED AN INDUSTRY UPDATE FOLLOWING THE REGULATORY SHIFTS IN GERMANY. GERMANY IS EXPECTED TO PASS THE CANNABIS ACT TODAY (FRIDAY), HERALDING A TRANSFORMATIVE ERA FOR THE MEDICAL CANNABIS INDUSTRY. THIS LEGISLATIVE MILESTONE, BY REMOVING CANNABIS FROM THE 'NARCOTICS ACT', IS SET TO SIGNIFICANTLY EASE THE PRESCRIPTION PROCESS FOR MEDICAL CANNABIS, HERALDING PROFOUND IMPLICATIONS FOR MEDICAL PROFESSIONALS, PATIENTS, AND COMPANIES OPERATING WITHIN TH.

PESG INDUSTRY UPDATES: GERMANY'S CANNABIS ACT AND ITS IMPACT ON THE MEDICAL CANNABIS LANDSCAPE

NEW YORK, AND HERZLIYA, ISRAEL, FEB. 13, 2024 (GLOBE NEWSWIRE) -- INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (DBA CANNDOC) ("INTERCURE" OR THE "COMPAN Y"), THE LEADING MEDICAL CANNABIS COMPANY IN ISRAEL AND OUTSIDE OF NORTH AMERICA, REPORTS TODAY THAT, FURTHER TO THE COMPANY'S PRESS RELEASE ISSUED ON OCTOBER 17, 2023, IN WHICH THE COMPANY PROVIDED AN UPDATE REGARDING THE STATUS OF THE SECURITY SITUATION IN ISRAEL, AND ITS IMPACT ON THE COMPANY AND ITS EMPLOYEES, THE COMPANY IS PROVIDING AN ADDITIONAL UPDATE REGARDING THE STATUS OF ITS FACILITY IN KIBBUTZ NIR OZ (THE SOUTHERN ISRAEL SITE).

InterCure Ltd.

INCR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

InterCure Ltd.

INCR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INCR